AKR1C2

Across TCGA pan-cancer cohorts, AKR1C2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of AKR1C2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where AKR1C2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types AKR1C2 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

KIRP, THCA, and KICH are the cancer types where AKR1C2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AKR1C2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	II,III,IV	+3.291	<.001	11	view →
THCA	Male	IV	−2.803	<.001	11	view →
KICH	Female	All	−2.566	<.001	11	view →
COAD	Female	II,III,IV	−1.509	<.001	10	view →
BRCA	All	III,IV	−3.541	<.001	8	view →
HNSC	All	II,III,IV	+1.262	.004	6	view →
LUSC	Male	All	+3.195	<.001	5	view →
STAD	All	All	−1.565	<.001	5	view →
LIHC	All	All	+1.037	<.001	3	view →
KIRC	All	II,III,IV	−0.705	.015	3	view →
LUAD	Male	All	+1.702	.022	2	view →
READ	Female	All	−1.365	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

AKR1C2–KIRP

Open the KIRP breakdown →